5-Amino-1MQ is a small-molecule quinolinium compound not a peptide that selectively inhibits nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme involved in the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Take supplements only as prescribed, avoid high doses unless necessary, and try to meet your vitamin needs through a balanced diet
Lancet Gastroenterol
At Rebalance, the cost of your visit will compose of your Naturopathic appointment and the cost of the vitamin B12 injection
Probe trials on day 9 consistently showed that high doses of Dihexa, regardless of administration method, significantly increased time spent in the target quadrant compared to scopolamine-impaired groups, indicating preserved learned task memory
